Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with…
Articles by Steve Bryson, PhD
A blood test that measures the levels of the M2BPGi protein accurately predicts the presence of moderate liver scarring, or…
Golexanolone, Umecrine Cognition’s investigational oral therapy, was generally safe and well tolerated in adults with primary biliary…
Having gestational diabetes increases the risk of adverse outcomes in pregnancy for women with intrahepatic cholestasis of pregnancy (ICP),…
Note: This story was updated Aug. 22, 2024, to clarify the timeline detailing the results of treatment. Atea Pharmaceuticals’ once-daily…
Drinking a small amount of alcohol each day did not raise the mortality risk among people in the early stages…
The composition of microbes is altered in the intestines of infants with biliary atresia, a type of liver disease…
One year of daily resmetirom, Madrigal Pharmaceuticals’ investigational oral therapy, was shown to successfully treat nonalcoholic steatohepatitis (NASH), a severe…
The U.S. Food and Drug Administration (FDA) will review CymaBay Therapeutics’ application for seladelpar, an oral…